Lansforsakringar Fondforvaltning AB publ Has $21.55 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Lansforsakringar Fondforvaltning AB publ increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,325 shares of the biopharmaceutical company’s stock after purchasing an additional 1,365 shares during the period. Lansforsakringar Fondforvaltning AB publ’s holdings in Regeneron Pharmaceuticals were worth $21,549,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Salomon & Ludwin LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $31,000. Traub Capital Management LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth about $38,000. E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 87.5% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 35 shares during the period. Finally, Berbice Capital Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 300.0% in the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 60 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 3,636 shares of company stock valued at $2,862,920. Company insiders own 7.02% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on REGN. Oppenheimer reissued an “outperform” rating and issued a $865.00 target price (up previously from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, February 16th. JPMorgan Chase & Co. lifted their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Finally, Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price objective for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $793.81.

Regeneron Pharmaceuticals Trading Down 0.3%

Regeneron Pharmaceuticals stock opened at $779.67 on Monday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The stock has a market capitalization of $82.43 billion, a P/E ratio of 18.76, a PEG ratio of 2.09 and a beta of 0.40. The stock has a 50-day simple moving average of $768.98 and a 200 day simple moving average of $674.68. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the firm earned $12.07 EPS. The firm’s revenue was up 2.5% compared to the same quarter last year. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be paid a dividend of $0.94 per share. The ex-dividend date is Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is 9.05%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.